Featured Publications
Psychiatric comorbidity as predictor and moderator of binge-eating disorder treatment outcomes: an analysis of aggregated randomized controlled trials
Lydecker JA, Grilo CM. Psychiatric comorbidity as predictor and moderator of binge-eating disorder treatment outcomes: an analysis of aggregated randomized controlled trials. Psychological Medicine 2021, 52: 4085-4093. PMID: 33849682, PMCID: PMC8514588, DOI: 10.1017/s0033291721001045.Peer-Reviewed Original ResearchBinge-eating disorderBinge-eating frequencyEating-disorder psychopathologyPsychiatric comorbidityBED treatment outcomesCognitive behavioral therapySelf-report measuresModerators of outcomeBinge-eating remissionDisorder treatment outcomesBehavioral weight lossRandomized-controlled trialCurrent psychiatric comorbidityMore effective interventionsTreatment outcomesAnxiety disordersTreatment researchSemi-structured interviewsMood comorbiditiesControl conditionPsychopathologyEffective interventionsComorbidity effectsWeight lossCurrent studyForm and Formulation: Examining the Distinctiveness of Body Image Constructs in Treatment-Seeking Patients With Binge-Eating Disorder
Lydecker JA, White MA, Grilo CM. Form and Formulation: Examining the Distinctiveness of Body Image Constructs in Treatment-Seeking Patients With Binge-Eating Disorder. Journal Of Consulting And Clinical Psychology 2017, 85: 1095-1103. PMID: 29083224, PMCID: PMC5679782, DOI: 10.1037/ccp0000258.Peer-Reviewed Original ResearchConceptsBody image variablesBody image disturbanceBody image constructsBinge-eating disorderImage constructImage variablesWeight/shape overvaluationBinge-eating frequencyInvestigator-based interviewBiopsychosocial featuresEating-disorder psychopathologyTreatment-seeking patientsShape preoccupationShape dissatisfactionShape overvaluationShape concernsCore aspectsCurrent studyTreatment formulationConstructsImportant distinctionDifferent aspectsOvervaluationPreoccupationDisordersCognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial
Grilo C, Lydecker J, Gueorguieva R. Cognitive‐behavioral therapy for binge‐eating disorder for non‐responders to initial acute treatments: Randomized controlled trial. International Journal Of Eating Disorders 2023, 56: 1544-1553. PMID: 37144325, PMCID: PMC10524840, DOI: 10.1002/eat.23975.Peer-Reviewed Original ResearchConceptsInitial acute treatmentBinge-eating disorderCognitive behavioral therapyAcute treatmentBinge-eating frequencyInitial interventionTherapist-led cognitive behavioural therapyInitial pharmacological treatmentTreat remission ratesEvidence-based treatmentsSingle-site trialAcute efficacyRemission rateAdult patientsInitial treatmentPharmacological treatmentPatientsPosttreatment assessmentBehavioral treatmentSufficient benefitTherapyDisordersInterventionTreatmentPharmacotherapy
2024
The children of parents who receive treatment for binge‐eating disorder experience improvements in disordered eating
Lydecker J, Ozbardakci E, Grilo C. The children of parents who receive treatment for binge‐eating disorder experience improvements in disordered eating. International Journal Of Eating Disorders 2024, 57: 745-751. PMID: 38308384, PMCID: PMC10947894, DOI: 10.1002/eat.24153.Peer-Reviewed Original ResearchBinge-eating disorderBinge eatingDisordered eating behaviorsEating behaviorsSecretive eatingParent changesDisordered eatingAssociated with disordered eating behaviorsEating-disorder psychopathologyEnd-of-treatment assessmentParental eating disordersAssociated with changesChildren of parentsCross-sectional workChild disordered eating behaviorsBinge-eating frequencyEating disordersSchool-aged childrenParental treatmentUntreated family membersParent medicationLongitudinal researchBingeBaseline assessmentEating
2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reductionNaltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial
Grilo C, Lydecker J, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychological Medicine 2023, 53: 7775-7784. PMID: 37366017, PMCID: PMC10751383, DOI: 10.1017/s0033291723001800.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderBinge-eating remissionAcute treatmentMaintenance treatmentBinge-eating frequencyDouble-blind placebo-controlled trialBehavioral weight loss therapyWeight lossCo-occurring obesitySuccessful acute treatmentPlacebo-controlled trialWeight loss therapySignificant additional weight lossSingle-site trialAdditional weight lossAcute efficacyRemission rateAdult patientsComorbid obesityBupropionInitial interventionPosttreatment assessmentRespondersPlacebo
2022
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial
Grilo CM, Lydecker JA, Fineberg SK, Moreno JO, Ivezaj V, Gueorguieva R. Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. American Journal Of Psychiatry 2022, 179: 927-937. PMID: 36285406, PMCID: PMC9722598, DOI: 10.1176/appi.ajp.20220267.Peer-Reviewed Original ResearchConceptsBehavioral weight loss therapyBinge-eating disorderPlacebo groupBupropion groupWeight lossRandomized double-blind placebo-controlled trialDouble-blind placebo-controlled trialLogistic regressionBinge-eating remissionPlacebo-controlled trialWeight loss therapyDouble-blind placeboSerious public health problemPublic health problemEvidence-based treatmentsRate of participantsBinge-eating frequencyBinge Eating DisorderMedical comorbiditiesRemission rateLoss therapyPercent weight lossMixed modelsFunctional impairmentSecondary measures
2020
Distinctiveness and significance of body dissatisfaction and overvaluation among Latinx/Hispanic and White men and women
Lydecker JA, Cotter EW, Grilo CM. Distinctiveness and significance of body dissatisfaction and overvaluation among Latinx/Hispanic and White men and women. International Journal Of Eating Disorders 2020, 54: 354-364. PMID: 33247450, PMCID: PMC7956228, DOI: 10.1002/eat.23413.Peer-Reviewed Original ResearchConceptsOvervaluation of weightBody image constructsDisorder psychopathologyWeight-related variablesBody imageImage constructBinge-eating frequencyAssociation of dissatisfactionBody dissatisfactionOnline batteryPsychopathologyWhite individualsCultural variablesDissatisfactionMain effectOvervaluationDepressionImportant distinctionDistinctivenessConstructsIndividualsFurther researchHispanic individualsHispanic adultsParticipantsNaltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study
Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. Clinical Therapeutics 2020, 43: 112-122.e1. PMID: 33218742, PMCID: PMC7902424, DOI: 10.1016/j.clinthera.2020.10.010.Peer-Reviewed Original ResearchConceptsBinge-eating disorderEating-disorder psychopathologyPilot RCTTreatment of BEDOutcome time pointDouble-blind treatmentPercentage of patientsControlled Pilot StudyDiscontinuation of medicationTreatment of bingeEvidence-based treatmentsBinge-eating frequencyBupropion combinationAdult patientsAdverse eventsComorbid obesitySecondary outcomesPrimary outcomeAcute effectsFunctional impairmentPlaceboLong-term effectsPatientsMost outcomesObesityTesting the Validity and Clinical Utility of the Severity Specifiers for Binge-Eating Disorder for Predicting Treatment Outcomes
Lydecker JA, Ivezaj V, Grilo CM. Testing the Validity and Clinical Utility of the Severity Specifiers for Binge-Eating Disorder for Predicting Treatment Outcomes. Journal Of Consulting And Clinical Psychology 2020, 88: 172-178. PMID: 31894997, PMCID: PMC7286612, DOI: 10.1037/ccp0000464.Peer-Reviewed Original ResearchConceptsBinge-eating disorderCognitive behavioral therapyBehavioral weight lossSeverity specifiersSelf-report measuresTreatment-seeking individualsBinge-eating frequencyBinge Eating DisorderEating-disorder psychopathologyClinical utilityTreatment outcomesSeverity categoriesPredicting Treatment OutcomeWeight lossFuture researchMain effectDepression scoresStatistical ManualParticipantsTesting treatmentsMultimodal treatmentPharmacological treatmentTreatment responseMedical CenterLarge series
2018
Comparing men and women with binge‐eating disorder and co‐morbid obesity
Lydecker JA, Grilo CM. Comparing men and women with binge‐eating disorder and co‐morbid obesity. International Journal Of Eating Disorders 2018, 51: 411-417. PMID: 29493793, PMCID: PMC5980708, DOI: 10.1002/eat.22847.Peer-Reviewed Original ResearchConceptsBody mass indexBinge-eating disorderEating-disorder psychopathologyBinge-eating episodesBinge-eating behaviorClinical presentationResearch cliniciansHigher body mass indexCo-morbid obesityDSM-IV disordersStructured Clinical InterviewEating Disorder Examination interviewAge of onsetBinge-eating frequencyRace/ethnicityMass indexBED diagnosisClinical InterviewYounger ageObesityExamination interviewWomenMenAgeDisorders